ArticleERJ open research2023
Biomarker-based clustering of patients with chronic obstructive pulmonary disease.
Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- A novel protective role for SULF1 in chronic obstructive pulmonary disease through systemic compensation and binding to KRT15.Respiratory research · 2026Article
- Stage-Dependent Reorganization of Inflammatory Biomarker Networks During Acute Exacerbations of COPD.Life (Basel, Switzerland) · 2026Article
- Regenerative therapeutics for chronic obstructive pulmonary disease.Pharmacological reviews · 2026Review
- The Evolving Landscape of COPD Typization.Medicina (Kaunas, Lithuania) · 2026Review
- Basophils activate oncostatin M receptor-expressing vagal sensory neurons.The Journal of allergy and clinical immunology · 2026Article
- Development and Validation of a Predictive Nomogram for Progression from Pre-COPD to Spirometric COPD: A Multicenter Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Cytokine- and Airflow-Based Clustering Identifies COPD Phenotypes with Differing Quantitative CT Features.International journal of chronic obstructive pulmonary disease · 2026Article
- Dyspnea in Chronic Obstructive Pulmonary Disease: Expert Assessment of Management in Clinical Practice.Pulmonary therapy · 2025Article
- Article
- Unsupervised Clustering of Vertebral Hounsfield Units in Opportunistic Chest CT for Stratifying Bone Mass Subtypes in a 2 Years' Period.Clinical interventions in aging · 2025Article
- Physical Activity and Systemic Biomarkers in Persons With COPD: Insights from a Web-Based Pedometer-Mediated Intervention.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- BASOPHILS ACTIVATE PRURICEPTOR-LIKE VAGAL SENSORY NEURONS.bioRxiv : the preprint server for biology · 2024Article
- Systemic Manifestations of COPD and the Impact of Dual Bronchodilation with Tiotropium/Olodaterol on Cardiac Function and Autonomic Integrity.Journal of clinical medicine · 2024Article
- Sputum Biomarkers in Wood and Tobacco Smoke Etiotypes of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2024Article
- Lung Function Trajectories and Associated Mortality among Adults with and without Airway Obstruction.American journal of respiratory and critical care medicine · 2023Article
- The AGE-RAGE Axis and the Pathophysiology of Multimorbidity in COPD.Journal of clinical medicine · 2023Review
- Machine Learning Identifies New Predictors on Restenosis Risk after Coronary Artery Stenting in 10,004 Patients with Surveillance Angiography.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: COPD has been associated repeatedly with single biomarkers of systemic inflammation, ignoring the complexity of inflammatory pathways. This study aimed to cluster patients with COPD based on systemic markers of inflammatory processes and to evaluate differences in their clinical characterisation and examine how these differences may relate to altered biological pathways. Methods: 213 patients with moderate-to-severe COPD in a clinically stable state were recruited and clinically characterised, which included a venous blood sample for analysis of serum biomarkers. Patients were clustered based on the overall similarity in systemic levels of 57 different biomarkers. To determine interactions among the regulated biomarkers, protein networks and biological pathways were examined for each patient cluster. Results: Four clusters were identified: two clusters with lower biomarker levels (I and II) and two clusters with higher biomarker levels (III and IV), with only a small number of biomarkers with similar trends in expression. Pathway analysis indicated that three of the four clusters were enriched in Rage (receptor for advanced glycation end-products) and Oncostatin M pathway components. Although the degree of airflow limitation was similar, the clinical characterisation of clusters ranged from 1) better functional capacity and health status and fewer comorbidities; 2) more underweight, osteoporosis and static hyperinflation; 3) more metabolically deranged; and 4) older subjects with worse functional capacity and higher comorbidity load. Conclusions: These new insights may help to understand the functionally relevant inflammatory interactions in the pathophysiology of COPD as a heterogeneous disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.